|Year : 2016 | Volume
| Issue : 4 | Page : 403-407
|Etiopathogenesis and therapeutic approach to adult onset acne
Sarabjit Kaur, Poonam Verma, Ankita Sangwan, Surabhi Dayal, Vijay Kumar Jain
Department of Dermatology and Venereology and Leprology, Pt. BD Sharma PGIMS, Rohtak, Haryana, India
|Date of Web Publication||7-Jul-2016|
House No. 401, Sector 14, Rohtak, Haryana
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Acne vulgaris is usually considered as a skin disorder that primarily affects adolescents reaching a peak at the age of 14-17 years in females and 16-19 years in males. However, recent epidemiologic studies have shown that a significant number of female patients aged >25 years experience acne. As it is regarded as a disease of teenagers, adults are more apprehensive and experience social anxiety. Hence, adult onset acne has become a matter of concern.
Keywords: Adult acne, hirsutism, hormonal acne, oral contraceptive pills
|How to cite this article:|
Kaur S, Verma P, Sangwan A, Dayal S, Jain VK. Etiopathogenesis and therapeutic approach to adult onset acne. Indian J Dermatol 2016;61:403-7
|How to cite this URL:|
Kaur S, Verma P, Sangwan A, Dayal S, Jain VK. Etiopathogenesis and therapeutic approach to adult onset acne. Indian J Dermatol [serial online] 2016 [cited 2021 Apr 15];61:403-7. Available from: https://www.e-ijd.org/text.asp?2016/61/4/403/185703
What was known?
Prime etiology in causing adult onset acne is known to be a hormonal imbalance. Hormonal therapy is considered as the main treatment modality.
| Introduction|| |
Incidence of adult onset acne (AOA) is increasing, and women comprise the majority of cases. , AOA is defined as chronic inflammatory disease of the pilosebaceous units occurring beyond the age of 25 years.  It commonly affects females (14%) between the age of 25 and 50 years. 
| Clinical Presentation|| |
Two distinct types:
Clinical differences between adolescent acne and adult onset acne are listed in [Table 1] [Figure 1].
- Persistent acne: Continuation of acne from adolescence to adult life or middle age. It is characterized by deep-seated painful inflammatory lesions, mainly papules, and nodules commonly involving jaw line, lower third of face and neck 
- Late-onset acne (chin and sporadic acne are recalcitrant in nature):  Acne occurring for the first time after the age of 25 years.
- Chin acne
- Sporadic acne: Etiology may embrace systemic illness or it may be idiopathic. 
|Figure 1: Inflammatory acne and excessive hair growth over cheeks and chin in a 30-year-old female patient|
Click here to view
| Etiology|| |
Genetic influence has been established by very high concordance between monozygotic twins. Goulden et al. reported that 50% patients had a first degree relative with AOA, which confirms familial predisposition. 
It is implicated in acne by action on adrenal-pituitary axis leading to increased androgen production, seborrhea, and comedogenesis. 
Cigarette smoke contains high amounts of arachidonic acid and polycyclic aromatic hydrocarbons, which stimulate a phospholipase A2-dependent inflammatory pathway. 
Adult acne have increased tendency of antibacterial resistant Propionibacterium acnes. 
Ingredients such as lanolin, petrolatum, and vegetable oils have been found to be comedogenic. 
Androgens can be synthesized locally in sebaceous glands from adrenal precursor hormone dehydroepiandrosterone sulfate. Mean serum androgen levels were found to be in higher normal range. This observation suggested that androgens act directly on sebaceous gland, or it may be more sensitive to the effect of androgens.  Hyperandrogenism has also been reported in studies by various studies.  Higher levels of 5α reductase (enzyme that converts testosterone to more androgenic dihydrotestosterone), 3α-androstanediol glucuronide, and androsterone glucuronide (tissue derived androgens) have been also found to be raised. It is unclear as to whether acne is mediated by serum androgens, locally produced androgens, or a combination of both. Studies have shown the association of polycystic ovarian disease (PCOD) with AOA in 52-82% of patients, reduced activity of 21α hydroxylase (late onset adrenal hyperplasia) in 11.8% patients; adrenal androgens were mildly raised implying end organ hypersensitivity as a central factor in pathogenesis of AOA.  List of systemic diseases associated with AOA has been summarized in [Table 2]. 
Insulin-like growth factor-1
Insulin-like growth factor-1 stimulates adrenal androgen production and also inhibits hepatic sex hormone-binding globulin (SHBG). Hyperinsulinemia and insulin resistance contribute to high prevalence of acne in women with PCOD. 
Follicular pore diameter increases with age
Allam  observed that patients with late-onset acne have larger pores than individuals of the same age who do not have acne.
Drugs are listed in [Table 3]. 
| Management|| |
The history should be followed by clinical examination and then relevant investigations [Figure 2].
|Figure 2: Investigative approach in a patient with adult onset acne. Abn: Abnormality, AN: Acanthosis nigricans, IR: Insulin resistance, HTN: Hypertension, MC: Menstrual cycle, DHEAS: Dehydroepiandrosterone sulfate, 17OHP: 17 hydroxyprogesterone, ACTH: Adrenocorticotropic hormone, PCOD: Polycystic ovarian disease, CAH: Congenital adrenal hyperplasia, NCAH: Nonclassical CAH, CS: Cushing syndrome, N/?#170;: Normal or increased, CT: Computed tomography, MRI: Magnetic resonance imaging|
Click here to view
Important history points include the following: ,,,
- Age of onset (sudden or late onset) - favors PCOD
- Family history
- Medical history of associated comorbidities such as obesity, diabetes, cardiovascular disease, or recent systemic illness
- History of any drug intake
- Obstetric/gynecological history including menstrual history (age of menarche, regular cycles), infertility, oral contraceptive pills (OCP), and hormonal intrauterine devices (progestogen) and pregnancy
- History of any precipitating cause:
- Sun exposure
- Seasonal variation
- Use of cosmetics and pomades
- Premenstrual flare.
Clinical assessment incorporates: ,,,
- Type of lesions
- Distribution of lesion
- Severity and grading of acne
- Features of cutaneous hyperandrogenism (CH):
- Hirsutism (modified Ferriman and Gallwey method)
- Androgenetic alopecia
- Acanthosis nigricans.
Signs of virilization:
Features of Cushing syndrome enumerated in [Figure 2].Appropriate investigations are mentioned in [Figure 2]. ,,, Hormone profile should ideally be performed on day 1-3 of menstrual cycle. Fasting sample should be preferred if the patient has amenorrhea. As hormones exhibit diurnal variation, these should be measured in the early morning. Oral contraceptive pills should be discontinued 4-6 weeks before hormone evaluation. 
- Deepening of voice
- Reduced muscle mass
- Decreased breast size.
| Treatment|| |
The general principles of treatment of adult acne are essentially the same as acne in younger age group except for some minor differences that should be considered. 
Topical retinoids should be considered as a first-line therapy for mild to moderate inflammatory acne as well as comedonal acne. When used in combination with topical or oral antimicrobial agent, apparently attain more rapid efficacy. However, since retinoids can irritate the older skin, shorter duration of application should be recommended. 
The preferred agents are second-generation tetracyclines (oxytetracycline, minocycline, and lymecycline) and erythromycin group of drugs.  These may show a slow response in AOA, and even treatment failure has been reported in 82% of adult women.  Patient should be warned regarding drug interactions if she is on concomitant oral contraceptives (OCs) and oral antibiotics should be stopped as soon as inflammatory lesions subside.
Seukeran and Cunliffe used low-dose systemic isotretinoin (0.25 mg/kg/day) for a period of 6 months which helped in resolution and remission of acne. 
Hormonal therapy may even be beneficial in patients with normal serum androgen levels.  Excellent candidates for hormonal therapy are: 
Hormone agents comprise two groups. 
- Recalcitrant acne
- PCOD, presence of anovulation (<9 cycles per year or cycles >40 days apart)
- SAHA syndrome: Seborrhea, acne, hirsutism, and androgenetic alopecia
- HAIR-AN syndrome: Hyperandrogenism, insulin resistance, acanthosis nigricans
- Drugs acting by decreasing androgen synthesis from adrenals and ovaries
Drugs acting by blocking androgen receptors
- Cyproterone acetate (CPA), spironolactone, drospirenone, and flutamide.
It acts by blocking androgen receptors. It is often used in combination with estrogens in the OCP, with ethinyl estradiol (EE) 35 ug. When used as monotherapy, it is given from day 1 to 10 of the menstrual cycle.  Common side effects include menstrual abnormalities, breast tenderness, nausea, vomiting, fluid retention, leg edema, headache, and liver dysfunction. 
It is an aldosterone and 5α receptor antagonist. It decreases androgen levels by increasing SHBG. It is given in a dose of 50-100 mg after food, but response can be seen with a lower dose of 25 mg once or twice daily.  It is cost effective and well tolerated.  Side effects include irregular menstrual cycles, breast tenderness, hypotension, and hyperkalemia.
It is a nonsteroidal androgen receptor blocker and is used in a dose of 250 mg twice daily. Liver functions should be monitored.  Bicalutamide, a new derivative, is less hepatotoxic than flutamide. 
Mechanism of action:
- Decrease ovarian androgen production
- Increase SHBG production
- Inhibit 5α reductase activity.
Common combinations used:
Started on day 1 of menstrual cycle (if contraception is required) or day 5 (if date of menstruation is to be maintained). ,,
- CPA 2 mg + EE 0.035 mg
- Drospirenone 3 mg + EE 0.03 mg
- Desogestrel 0.15 mg + EE 0.03 mg
- Desogestrel 0.15 mg + EE 0.02 mg.
Weight gain, breast tenderness, breakthrough bleeding, stroke, myocardial infarction, melasma and mood changes.
These are reserved for the patients with congenital or nonclassical adrenal hyperplasia. 
Metformin and thiazolidinediones (rosiglitazone/pioglitazone)
These agents act by improving insulin sensitivity, and subsequently, decrease circulating androgen levels. In addition, these agents have a role in the treatment of PCOD. Metformin is given in a dose of 500 mg- 2000mg/day. Its side effects are diarrhea, nausea, taste changes, and lactic acidosis.  Upcoming drugs with controversial role: Ketoconazole, lymecycline, oral zinc, and cimetidine: these newer drugs seem to have antiandrogenic role. ,
For cyproterone acetate and flutamide, periodic monitoring of liver function tests is required. Spironolactone has a tendency to cause hyperkalemia and ECG changes. So S. potassium and ECG should be checked. For newer generation OCs, no specific monitoring is warrented unless patient is in high risk group. Glucocorticoids warrants monitoring of blood pressure, blood sugar and electrolytes. ,
Blue light therapy
It has a significant role in reducing mild-to-moderate inflammatory acne. Porphyrin (coproporphyrin III) produced within P. acnes releases free radicals on irradiation by 420 nm and shorter wavelengths of light; these free radicals effectively kill the bacteria. 
Treatment of acne in pregnant, lactating women, or those who wish to conceive
Topical medication is the first-line treatment for acne vulgaris in this group. These include antibiotics (erythromycin and clindamycin), azelaic acid, and salicylic acid. Second-line treatment consists of oral macrolides (erythromycin azithromycin). Blue-violet or red light phototherapy may be used in addition to topical and/or oral therapies. Hormonal therapy, antibiotics consisting of tetracyclines, and both oral and topical retinoids should be avoided. 
| Conclusion|| |
AOA is generally considered refractory to the treatment. A proper history and clinical assessment aids in reaching to a correct diagnosis and hence management accordingly.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Williams C, Layton AM. Persistent acne in women: Implications for the patient and for therapy. Am J Clin Dermatol 2006;7:281-90.
Kim GK, Del Rosso JQ. Oral spironolactone in post-teenage female patients with acne vulgaris: Practical considerations for the clinician based on current data and clinical experience. J Clin Aesthet Dermatol 2012;5:37-50.
Seirafi H, Farnaghi F, Vasheghani-Farahani A, Alirezaie NS, Esfahanian F, Firooz A, et al.
Assessment of androgens in women with adult-onset acne. Int J Dermatol 2007;46:1188-91.
Balta I, Ekiz O, Ozuguz P, Ustun I, Karaca S, Dogruk Kacar S, et al.
Insulin resistance in patients with post-adolescent acne. Int J Dermatol 2015;54:662-6.
Marks R. Acne and its management beyond the age of 35 years. Am J Clin Dermatol 2004;5:459-62.
Goulden V, Clark SM, Cunliffe WJ. Post-adolescent acne: A review of clinical features. Br J Dermatol 1997;136:66-70.
Layton AM. Disorders of the sebaceous glands. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's Textbook of Dermatology. 8 th
ed. USA: Wiley Blackwell; 2010. p. 42.34.
Khunger N, Kumar C. A clinico-epidemiological study of adult acne: Is it different from adolescent acne? Indian J Dermatol Venereol Leprol 2012;78:335-41.
Uzuncakmak TK, Karadag AS, Akdeniz N. Acne and systemic diseases. EMJ Dermatol 2015;3:73-8.
Allam SG. Acne Vulgaris in the Sixth Decade and Beyond [MSc Thesis]. Cardiff: University of Wales; 1991.
Lakshmi C. Hormone therapy in acne. Indian J Dermatol Venereol Leprol 2013;79:322-37.
Kubba R, Bajaj AK, Thappa DM, Sharma R, Vedamurthy M, Dhar S, et al.
Acne in India: Guidelines for management - IAA consensus document. Indian J Dermatol Venereol Leprol 2009;75 Suppl 1:1-62.
Witchel SF. Nonclassic congenital adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes 2012;19:151-8.
Seukeran DC, Cunliffe WJ. Acne vulgaris in the elderly: The response to low-dose isotretinoin. Br J Dermatol 1998;139:99-101.
Ebede TL, Arch EL, Berson D. Hormonal treatment of acne in women. J Clin Aesthet Dermatol 2009;2:16-22.
Gold MH, Andriessen A, Biron J, Andriessen H. Clinical efficacy of self-applied blue light therapy for mild-to-moderate facial acne. J Clin Aesthet Dermatol 2009;2:44-50.
Kong YL, Tey HL. Treatment of acne vulgaris during pregnancy and lactation. Drugs 2013;73:779-87.
What is new?
Adult onset acne is a multifactorial disease. Thus, investigative and therapeutic approach is needed to avoid resistance to therapy. Low dose isotretinoin and new emerging modalities such as blue light therapy are proven to have a beneficial role.
[Figure 1], [Figure 2]
[Table 1], [Table 2], [Table 3]
| Article Access Statistics|
| Viewed||7324 |
| Printed||145 |
| Emailed||1 |
| PDF Downloaded||594 |
| Comments ||[Add] |